Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up

Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). However, it remains unknown whether treatment should be continued until progression or discontinued in patients with good response. We present the history of a woman diagnosed with RCC in 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerin, Mathilde, Salem, Naji, Walz, Jochen, Dermeche, Slimane, Gravis, Gwenaelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851250/
https://www.ncbi.nlm.nih.gov/pubmed/24073932
http://dx.doi.org/10.1186/1477-7819-11-243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851250/
https://www.ncbi.nlm.nih.gov/pubmed/24073932
http://dx.doi.org/10.1186/1477-7819-11-243

Ejemplares similares